PA
LXRX icon

Profund Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Profund Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117K Buy
+48,586
New +$94.6K ﹤0.01% 1139
2015
Q2 		– Sell
-1,812
Closed -$12K – 1507
2015
Q1 		$12K Buy
1,812
+184
+11% +$1.26K ﹤0.01% 1529
2014
Q4 		$10K Sell
1,628
-31
-2% -$250 ﹤0.01% 1437
2014
Q3 		$16K Sell
1,659
-1,750
-51% -$18.7K ﹤0.01% 1307
2014
Q2 		$38K Buy
3,409
+66
+2% +$709 ﹤0.01% 1543
2014
Q1 		$40K Buy
3,343
+1,309
+64% +$16.7K ﹤0.01% 1580
2013
Q4 		$26K Buy
2,034
+363
+22% +$5.78K ﹤0.01% 1685
2013
Q3 		$28K Buy
1,671
+55
+3% +$922 ﹤0.01% 1635
2013
Q2 		$25K Buy
+1,616
New +$24.6K ﹤0.01% 1375

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Profund Advisors's LXRX Position: Q2 2026 in Review

Profund Advisors opened a new position in Lexicon Pharmaceuticals (LXRX) in Q2 2026: 48,586 shares worth $117K. The stake represents ﹤0.01% of the portfolio and ranks #1139 among its holdings. This is a return to the name: Profund Advisors previously reported a position in LXRX as recently as Q1 2015.

Profund Advisors first reported a position in LXRX in Q2 2013 and has held it in 9 quarters since. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Profund Advisors held 48,586 shares of Lexicon Pharmaceuticals worth $117K as of Q2 2026.
  • Lexicon Pharmaceuticals was a new Profund Advisors position in Q2 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Profund Advisors's portfolio in Q2 2026, its #1139 holding.
  • Profund Advisors first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 9 quarters since.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.